You are viewing: China POP Treatment and Management / Pelvic Organ Prolapse Market analysis

The China POP Treatment and Management / Pelvic Organ Prolapse Market was valued at $3.87 Million in 2025 and projected to reach to $5.79 Million by 2030, representing a compound annual growth rate of 8.4%. China's pelvic organ prolapse treatment and management market is positioned for sustained growth through 2030, driven by demographic shifts and healthcare system modernization.

China POP Treatment and Management / Pelvic Organ Prolapse Market (2025-2030) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

China POP Treatment and Management / Pelvic Organ Prolapse Market Trends and Insights

  • This growth trajectory reflects China's aging population demographics and rising healthcare expenditure, which are driving increased diagnosis and treatment adoption across urban and rural regions.
  • China's market is expanding faster than the global average of 6.6% CAGR, underscoring the country's significant opportunity in women's health management. The China market benefits from improving healthcare infrastructure, growing awareness of pelvic floor disorders, and expanding access to both conservative and surgical treatment options.
  • China's healthcare system modernization and increased investment in gynecological care are accelerating market penetration.
  • Between 2025 and 2030, China is expected to capture substantial market share within the Asia Pacific region, driven by a large patient population and evolving clinical practice standards that emphasize early intervention and comprehensive management strategies..

Key Market Statistics

  • CAGR (2025-2030) 8.4% CAGR
  • Market Size, 2025 ~USD 3.87 Million
  • Forecast, 2030 ~USD 5.79 Million
  • Country China

China POP Treatment and Management / Pelvic Organ Prolapse Market Overview

Aging Population Driver :

China's rapidly aging demographic, with over 280 million people aged 60+, is significantly increasing POP prevalence and creating substantial demand for treatment and management solutions across the country.

Healthcare Expenditure Growth :

Rising healthcare spending in China, coupled with improved insurance coverage and government health initiatives, is enabling greater access to POP diagnosis and treatment in both urban and rural healthcare facilities.

Urban-Rural Expansion :

Market growth is being driven by expanding healthcare infrastructure in tier-2 and tier-3 cities, where awareness campaigns and improved gynecological services are increasing POP case identification and treatment adoption.

Strong CAGR Performance :

China's market is growing at 8.4% CAGR (2025-2030), outpacing the global average of 6.6%, reflecting accelerating demand for both conservative management and surgical intervention options.

China POP Treatment and Management / Pelvic Organ Prolapse Market Dynamics

  • The country's aging population, combined with increased awareness among healthcare providers and patients, is expanding the addressable market across metropolitan and secondary cities.
  • Government initiatives promoting women's health and improved reimbursement policies are facilitating greater treatment adoption.
  • The market will likely see increased investment in minimally invasive surgical techniques and conservative management options tailored to Chinese patient populations.
  • Competition among medical device manufacturers and healthcare providers is expected to intensify, driving innovation and improving accessibility to POP solutions..

Related Ecosystem

Medical Devices

Top Technologies
  • Polymerase Chain Reaction (PCR)
  • Magnetic Resonance Imaging (MRI)
  • Disposable Autoinjectors
  • Pulse Oximeters
  • Blood Pressure Monitors
Top Companies
  • Medtronic plc
  • Abbott Laboratories
  • Stryker Corporation
  • Becton, Dickinson and Company
  • CONMED Corporation

    Key Takeaways

    • China's POP market is valued at USD 3.87 million in 2025 and will reach USD 5.79 million by 2030, growing at 8.4% CAGR.
    • China's market growth rate outpaces the global average, reflecting strong demographic and healthcare investment tailwinds.
    • China's aging population and improved healthcare access are primary drivers of increased POP diagnosis and treatment demand.
    • China represents a high-growth opportunity within Asia Pacific, supported by modernizing healthcare infrastructure and rising clinical awareness.

    POP Treatment and Management / Pelvic Organ Prolapse Market Report Scope

    Report Metric Details
    Base Year 2025
    Fastest Growing Segment SACROCOLPOPEXY (Type)
    Forecast Period 2025–2030
    Growth Rate CAGR of 6.6% from 2025 to 2030
    Largest Segment SURGICAL (Treatment)
    Market Size Base Year (Billions) ~USD 0.77 (2025)
    Revenue Forecast (Billions) ~USD 1.06 (2030)
    Segments Covered Product, Treatment, Type, Application, End User

    China POP Treatment and Management / Pelvic Organ Prolapse Market Report Segmentation

    5 segment dimensions are covered across the global market.

    By Product

    • Biological Grafts
    • Diagnostic & Assessment Tools
    • Pelvic Floor Therapy Devices
    • Robotic Surgery Systems
    • Sutures
    • Synthetic Mesh
    • Vaginal Pessaries

    By Treatment

    • Non-Surgical
    • Surgical

    By Type

    • Colpocleisis
    • Colporrhaphy
    • Pelvic Floor Muscle Therapy
    • Sacrocolpopexy
    • Sacrohysteropexy
    • Uterosacral Or Sacrospinous Ligament Fixation
    • Vaginal Pessary Management

    By Application

    • Cystocele
    • Enterocele
    • Rectocele
    • Urethrocele
    • Uterine Prolapse

    By End User

    • Ambulatory Surgery Centers
    • Hospitals
    • Other End Users
    • Specialty Clinics

    Target Audience

    • Medical Device Manufacturers : Manufacturers of POP treatment devices and surgical instruments need China-specific market data to develop localized product strategies, navigate regulatory requirements, and identify distribution partnerships in this high-growth market.
    • Healthcare Providers and Hospital Networks : Chinese hospitals and gynecological clinics require market insights to optimize POP service offerings, understand patient demand patterns, and plan capital investments in treatment infrastructure and training.
    • Pharmaceutical and Biotech Companies : Companies developing conservative management solutions and pharmaceutical treatments for POP need China-specific epidemiological data and market dynamics to guide R&D investments and commercialization strategies.
    • Healthcare Investors and Private Equity : Investment firms evaluating opportunities in China's women's health sector require detailed market sizing, growth projections, and competitive analysis to assess portfolio companies and identify acquisition targets.
    • Healthcare Consultants and Market Researchers : Consulting firms and research organizations supporting clients in the Chinese healthcare market need comprehensive, country-specific data on POP treatment trends, reimbursement policies, and competitive dynamics.

    Key Companies in the China POP Treatment and Management / Pelvic Organ Prolapse Market

    CompanyHQOwnershipStrongest segments
    BOSTON SCIENTIFIC CORPORATIONUnited StatesPublic CompanyCardiovascular (CRM, structural heart, peripheral interventions, LAAC),MedSurg Endoscopy (GI, pancreaticobiliary, single-use scopes, infection prevention),Urology and Pelvic Health,
    COOPERCOMPANIESUnited StatesPublic CompanySpherical contact lenses,Toric and multifocal contact lenses,Fertility consumables, equipment, and services,
    JOHNSON & JOHNSONUnited StatesPublic CompanyOncology,Immunology,Neuroscience and Other Innovative Medicine,
    GE HEALTHCAREUnited StatesPublic CompanyImaging,Advanced Visualization Solutions (AVS),Patient Care Solutions (PCS),
    INTEGRA LIFESCIENCES CORPORATIONUnited StatesPublic CompanyNeurosurgery & Neurocritical Care (Codman Specialty Surgical),ENT, Navigation & Surgical Instrumentation,Tissue Technologies – Wound, Skin & Reconstruction,
    FEG TEXTILTECHNIK FORSCHUNGS- UND ENTWICKLUNGSGESELLSCHAFT MBHGermanyPrivate CompanyContract R&D and prototyping,Process engineering and scale-up services,Consulting, testing, and training,

    BOSTON SCIENTIFIC CORPORATION

    Boston Scientific Corporation is a publicly traded medical device company founded in 1979 and headquartered in the United States. With 59,000 employees, the company develops and manufactures a broad range of medical devices and technologies for various healthcare applications.

    COOPERCOMPANIES

    Cooper Companies is a publicly traded medical device company founded in 1958 and headquartered in the United States. With 15,000 employees, the company operates in the contact lens and eye care markets.

    JOHNSON & JOHNSON

    Johnson & Johnson is a publicly traded multinational healthcare company founded in 1886 and based in the United States. With 138,200 employees, the company operates across pharmaceuticals, medical devices, and consumer health segments.

    GE HEALTHCARE

    GE Healthcare is a publicly traded medical technology company founded in 2022 and headquartered in the United States. The company employs 54,000 people and provides healthcare imaging, monitoring, and diagnostic solutions.

    INTEGRA LIFESCIENCES CORPORATION

    Integra LifeSciences Corporation is a publicly traded medical device company founded in 1989 and based in the United States. With 4,427 employees, the company develops and manufactures surgical instruments and regenerative medicine products.

    FEG TEXTILTECHNIK FORSCHUNGS- UND ENTWICKLUNGSGESELLSCHAFT MBH

    FEG Textiltechnik Forschungs- und Entwicklungsgesellschaft mbH is a privately held company founded in 1991 and headquartered in Germany. The company specializes in textile technology research and development.

    Reasons to Buy this Report

    • Market-Specific Growth Insights : Understand China's unique 8.4% CAGR trajectory and identify high-growth opportunities within the country's distinct urban-rural healthcare landscape and demographic trends.
    • Competitive Landscape Analysis : Gain detailed intelligence on local and international competitors operating in China's POP market, including market positioning, pricing strategies, and distribution channels specific to Chinese healthcare systems.
    • Regulatory and Reimbursement Framework : Access comprehensive analysis of China's healthcare regulations, insurance coverage policies, and government health initiatives that directly impact POP treatment adoption and market accessibility.
    • Regional Expansion Strategy : Develop targeted market entry and expansion strategies for tier-1, tier-2, and tier-3 Chinese cities with data-driven insights on healthcare infrastructure maturity and patient demographics.
    • Investment and Partnership Opportunities : Identify strategic investment, partnership, and acquisition opportunities within China's rapidly evolving POP treatment market with detailed financial projections through 2030.

    Frequently asked questions

    What is the current market size of POP treatment in China?

    China's pelvic organ prolapse treatment and management market was valued at USD 3.87 million in 2025.

    What is the projected market size for China's POP market by 2030?

    China's POP market is forecast to reach USD 5.79 million by 2030, representing significant growth over the five-year period.

    What is the CAGR for China's POP treatment market?

    China's pelvic organ prolapse market is expected to grow at a compound annual growth rate of 8.4% from 2025 to 2030.

    How does China's POP market growth compare to global trends?

    China's market CAGR of 8.4% exceeds the global average of 6.6%, indicating faster expansion driven by demographic and healthcare infrastructure factors.

    What factors are driving growth in China's POP market?

    China's market growth is driven by an aging population, rising healthcare expenditure, improved diagnostic capabilities, and increased awareness of pelvic floor disorders.

    RESEARCH METHODOLOGY

    The study involved major activities in estimating the current market size for the POP Treatment and Management / Pelvic Organ Prolapse market. Exhaustive secondary research was done to collect information on the POP Treatment and Management / Pelvic Organ Prolapse industry. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain using primary research. Different approaches, such as top-down and bottom-up, were employed to estimate the total market size. After that, the market breakup and data triangulation procedures were used to estimate the market size of the segments and subsegments of the POP Treatment and Management / Pelvic Organ Prolapse market.

    The four steps involved in estimating the market size are:

    Secondary Research

    The secondary research process involved the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B Hoovers), white papers, annual reports, investor presentations, SEC filings of companies and publications from government sources [such as National Institutes of Health (NIH), US FDA, US Census Bureau, World Health Organization (WHO), Global Burden of Disease Study, and Centers for Medicare and Medicaid Services (CMS)] to identify and collect information for the global POP Treatment and Management / Pelvic Organ Prolapse market study. Secondary sources were also used to obtain important information about the key players, market classification & segmentation according to industry trends to the bottom-most level, and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.

    Primary Research

    In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side included industry experts such as CEOs, vice presidents, marketing and sales directors, technology & innovation directors, and related key executives from various key companies and organizations in the POP Treatment and Management / Pelvic Organ Prolapse market. The primary sources from the demand side included pharmaceutical companies, biotechnology companies, CROs, medical device companies, and research academics and universities. Primary research was conducted to validate the market segmentation, identify key players in the market, and gather insights on key industry trends & key market dynamics.

    The following is a breakdown of the primary respondents:

    POP Treatment and Management / Pelvic Organ Prolapse Market

    Note 1: Other designations include sales, marketing, and product managers.

    Note 2: Companies are classified into tiers based on their total revenues. As of 2024, Tier 1 = >USD 100 million, Tier 2 = USD 10 million to USD 100 million, and Tier 3 = < USD 10 million.

    To know about the assumptions considered for the study, download the pdf brochure

    Market Size Estimation

    For the global market value, annual revenues were calculated based on the revenue mapping of major product manufacturers and OEMs active in the global POP Treatment and Management / Pelvic Organ Prolapse market. All the major service providers were identified at the global and/or country/regional level. Revenue mapping for the respective business segments/subsegments was done for the major players. The global POP Treatment and Management / Pelvic Organ Prolapse market was split into various segments and sub-segments based on:

    • List of major players operating in the products market at the regional and/or country level
    • Product mapping of POP Treatment and Management / Pelvic Organ Prolapse providers at the regional and/or country level
    • Mapping of annual revenue generated by listed major players from POP Treatment and Management / Pelvic Organ Prolapse (or the nearest reported business unit/product category)
    • Extrapolation of the revenue mapping of the listed major players to derive the global market value of the respective segments/subsegments
    • Summation of the market value of all segments/subsegments to arrive at the global POP Treatment and Management / Pelvic Organ Prolapse market
    • The above-mentioned data was consolidated and added with detailed inputs and analysis from MarketsandMarkets and presented in this report.

    The research methodology used to estimate the market size includes the following:

    POP Treatment and Management / Pelvic Organ Prolapse Market

    Data Triangulation

    After arriving at the overall market size by applying the processes mentioned above, the total market was split into several segments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

    Market Definition

    Pelvic organ prolapse (POP) is a condition in which the pelvic organs—such as the vagina, uterus, bladder, or rectum—descend from their normal anatomical positions. This occurs when the pelvic floor, composed of muscles, ligaments, and connective tissues that provide structural support to these organs, is weakened or stretched. The pelvic floor functions as a supportive structure beneath the pelvic organs. When these supportive structures lose strength or elasticity, the organs may shift out of place or protrude into the vaginal canal. Common causes of pelvic floor weakening include childbirth, aging, and other factors that increase intra-abdominal pressure.

    Stakeholders

    • Pelvic Organ Prolapse Product Manufacturers
    • Research and Consulting Firms
    • Distributors of Pelvic Organ Prolapse Devices
    • Private Insurance Companies
    • Gynecologists and Urogynecologists
    • Healthcare Institutes (Hospitals, Medical Schools, Diagnostic Centers, and Outpatient Clinics)
    • Research Institutes
    • Venture Capitalists

    Report Objectives

    • To define, describe, segment, and forecast the global POP Treatment and Management / Pelvic Organ Prolapse market by product, treatment, application, end user, and region
    • To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
    • To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall POP Treatment and Management / Pelvic Organ Prolapse market
    • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
    • To forecast the size of the market segments with respect to five regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa
    • To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
    • To benchmark players within the market using the proprietary company evaluation matrix framework, which analyzes market players on various parameters within the broad categories of business and product excellence
    • To study the impact of AI/Gen AI on the market, along with the macroeconomic outlook for each region

    Get the Full POP Treatment and Management / Pelvic Organ Prolapse Market Report

    Full forecast, segment splits, and company analysis for all POP Treatment and Management / Pelvic Organ Prolapse Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status